| Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo A Roghanian, I Teige, L Mårtensson, KL Cox, M Kovacek, A Ljungars, ... Cancer cell 27 (4), 473-488, 2015 | 149 | 2015 |
| Antibodies to costimulatory receptor 4-1BB enhance anti-tumor immunity via T regulatory cell depletion and promotion of CD8 T cell effector function SL Buchan, L Dou, M Remer, SG Booth, SN Dunn, C Lai, M Semmrich, ... Immunity 49 (5), 958-970. e7, 2018 | 137 | 2018 |
| The soluble isoform of CTLA‐4 as a regulator of T‐cell responses FJ Ward, LN Dahal, SK Wijesekera, SK Abdul‐Jawad, T Kaewarpai, H Xu, ... European journal of immunology 43 (5), 1274-1285, 2013 | 133 | 2013 |
| Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies X Yu, HTC Chan, CM Orr, O Dadas, SG Booth, LN Dahal, CA Penfold, ... Cancer cell 33 (4), 664-675. e4, 2018 | 98 | 2018 |
| Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies TRW Tipton, A Roghanian, RJ Oldham, MJ Carter, KL Cox, CI Mockridge, ... Blood, The Journal of the American Society of Hematology 125 (12), 1901-1909, 2015 | 89 | 2015 |
| STING activation reverses lymphoma-mediated resistance to antibody immunotherapy LN Dahal, L Dou, K Hussain, R Liu, A Earley, KL Cox, S Murinello, I Tracy, ... Cancer research 77 (13), 3619-3631, 2017 | 76 | 2017 |
| Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment AH Turaj, K Hussain, KL Cox, MJJ Rose-Zerilli, J Testa, LN Dahal, ... Cancer cell 32 (6), 777-791. e6, 2017 | 71 | 2017 |
| FcγR requirements leading to successful immunotherapy LN Dahal, A Roghanian, SA Beers, MS Cragg Immunological reviews 268 (1), 104-122, 2015 | 56 | 2015 |
| Improved multiplex immunohistochemistry for immune microenvironment evaluation of mouse formalin-fixed, paraffin-embedded tissues N Sorrelle, D Ganguly, ATA Dominguez, Y Zhang, H Huang, LN Dahal, ... The Journal of Immunology 202 (1), 292-299, 2019 | 51 | 2019 |
| Development and characterization of monoclonal antibodies specific for mouse and human Fcγ receptors AL Tutt, S James, SA Laversin, TRW Tipton, M Ashton-Key, RR French, ... The Journal of Immunology 195 (11), 5503-5516, 2015 | 51 | 2015 |
| Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? V Reddy, LN Dahal, MS Cragg, M Leandro Drug discovery today 21 (8), 1330-1338, 2016 | 49 | 2016 |
| New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B) A Roghanian, RJ Stopforth, LN Dahal, MS Cragg Journal of leukocyte biology 103 (6), 1077-1088, 2018 | 36 | 2018 |
| Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy? FJ Ward, LN Dahal, RC Khanolkar, SP Shankar, RN Barker Immunotherapy 6 (10), 1073-1084, 2014 | 30 | 2014 |
| Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus LN Dahal, N Basu, H Youssef, RC Khanolkar, RN Barker, LP Erwig, ... Arthritis research & therapy 18, 1-11, 2016 | 29 | 2016 |
| Shaving is an epiphenomenon of type I and II anti-CD20–mediated phagocytosis, whereas antigenic modulation limits type I monoclonal antibody efficacy LN Dahal, CY Huang, RJ Stopforth, A Mead, K Chan, JX Bowater, ... The Journal of Immunology 201 (4), 1211-1221, 2018 | 22 | 2018 |
| Investigating the role of indoleamine 2, 3-dioxygenase in acute myeloid leukemia: a systematic review G Wells, PT Kennedy, LN Dahal Frontiers in immunology 12, 651687, 2021 | 20 | 2021 |
| Antibodies specifically directed to the soluble form of ctla-4 FJ Ward, RN Barker, LN Dahal | 20 | 2017 |
| Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia J Bloehdorn, A Braun, A Taylor-Weiner, BMC Jebaraj, S Robrecht, ... Nature Communications 12 (1), 5395, 2021 | 19 | 2021 |
| On the road to immunotherapy—prospects for treating head and neck cancers with checkpoint inhibitor antibodies FJ Ward, LN Dahal, R Abu-Eid Frontiers in immunology 9, 2182, 2018 | 18 | 2018 |
| PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis MJ Carter, KL Cox, SJ Blakemore, AH Turaj, RJ Oldham, LN Dahal, ... Leukemia 31 (6), 1423-1433, 2017 | 18 | 2017 |
